Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

1–7 In particular, an association between some of the connective-tissue diseases and Hashimoto's thyroiditis (lymphadenoid goiter) has recently seemed likely. 6,8,9 Many reports of this ...